Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16684474 | 1.00 | HSD11B1 (0.84) | HSD11B1HSD11B2 | |
| SCHEMBL16684442 | 0.91 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL15891907 | 0.91 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL16666889 | 0.90 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL16945742 | 0.90 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL16940713 | 0.89 | HSD11B1 (0.82) | HSD11B1 | |
| SCHEMBL16666610 | 0.89 | HSD11B1 (0.86) | HSD11B1 | |
| SCHEMBL16666559 | 0.89 | HSD11B1 (0.82) | HSD11B1 | |
| SCHEMBL14676041 | 0.88 | HSD11B1 (0.66) | HSD11B1HSD11B2 | |
| SCHEMBL14675383 | 0.88 | HSD11B1 (0.66) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865664-B1 | NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | BAMICHEM CO LTD (KR) | 2017-11-01 | — | — | EP | disclosed |
| US-9464044-B2 | Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) | 2016-10-11 | — | — | US | disclosed |
| US-20150210635-A1 | NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2015-07-30 | — | — | US | disclosed |
| EP-2865664-A1 | NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | BAMICHEM CO., LTD (KR) | 2015-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210635-A1 | NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.